CPIX
Cumberland Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 0
High Gross Profit Margin
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CPIX
Cumberland Pharmaceuticals Inc.
The largest biopharmaceutical company in the Mid-South
1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203
--
Cumberland Pharmaceuticals Inc., was incorporated in 1999. Focusing on the acquisition, development and commercialization of branded prescription products, it is a growing specialty pharmaceutical company. The company's main target markets are acute care and gastrointestinal diseases in hospitals, which the company believes can effectively penetrate the relatively concentrated physician prescribing base through a relatively small, targeted sales force. The company is committed to providing innovative products that improve the quality of care for patients and address difficult medical requirements. The Company has product development and commercial capabilities and believes it can leverage its existing infrastructure to support its expected growth. The company's management team consists of veterans in the pharmaceutical industry. It has extensive experience in business development, product development, business and finance. The company's business development team identifies, evaluates and negotiates product acquisition, import licensing and export licensing opportunities. The company's product development team develops proprietary product formulations, manages its clinical trials, prepares all regulatory submissions and manages its medical call center. The company's high-quality and professional manufacturers oversee the production of its products. The company's marketing and sales professionals are responsible for its commercial activities, while the company works closely with third-party distribution partners to ensure availability and delivery of its products.
Earnings Call
Q1/2025
Estimate EPS--
Actual EPS0.16
Estimate Revenue--
Actual Revenue11.70M
Cumberland Pharmaceuticals' Q1 2025: Navigating Contradictions in Clinical Progress and Financial Growth
May 07,2025 07:28
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS--
Actual EPS-0.02
Estimate Revenue--
Actual Revenue10.80M
Cumberland Pharmaceuticals Q2 2025: Unpacking Key Contradictions in Production, Margins, and Growth Outlook
Aug 06,2025 02:01
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CPIX has released its 2025 Q3 earnings. EPS was reported at -0.06, versus the expected 0, missing expectations. The chart below visualizes how CPIX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CPIX has released its 2025 Q3 earnings report, with revenue of 8.29M, reflecting a YoY change of -8.73%, and net profit of -1.95M, showing a YoY change of -26.81%. The Sankey diagram below clearly presents CPIX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
